SDC1 and Miyoshi myopathy: The vaccine is composed of a unique combination of four immunogenic peptides (XBP1US184–192, XBP1SP367–375, CD138260–268, and CS1239–247) derived from specific tumor target antigens (XBP1, CD138, and CS1, respectively) highly expressed on MM cells.